Читать книгу Drug Transporters - Группа авторов - Страница 70

Multiple polymorphisms have been identified in SLC22A16 (Table 2.3), and one (c.146A>G) may contribute to interindividual pharmacokinetic variation of doxorubicin and doxorubicinol in Asian breast cancer patients [108]. Additionally, a GWAS investigating metabolite levels in whole blood identified polymorphisms in SLC22A16 that were associated with levels of two long‐chain acylcarnitines [87].